In consultation: Guidance and quality standards
Showing 1 to 10 of 35
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Mavorixafor for treating WHIM syndrome ID3946 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6625 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Tozorakimab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease [ID6711] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID6463 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Polyendocrine Metabolic Ovarian Syndrome (PMOS) | Draft guidance | NICE guideline | |
| Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease ID6733 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Draft guidance | Technology appraisal guidance | |
| Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over (review of HST31) [ID6598] | Draft guidance | Highly specialised technology | |
| Bladder cancer: diagnosis and management (update) | Scoping | NICE guideline | |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |